A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
← catalyst calendarNCT05718570 · readout in 2,310 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
400estimated
Sites
55
Countries
France, Germany, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-03 | actual | When the study began enrolling |
| Primary completion | 2032-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Adult Growth Hormone Deficiency
Intervention
- Drug: Somapacitan
Primary outcomes
what the primary-completion date above is the date OFNumber of Adverse drug reaction (ADRs)
measured From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Incident Neoplasm
measured From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Incident Diabetes Mellitus type 2
measured From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed